Expression of IL-1Ra and ANL3 via Cartilage-Penetrating Lipid Nanoparticles Achieves Simultaneous Inhibition of Arthritis Inflammation and Cartilage Regeneration
Background
Arthritis is considered a representative intractable disease in an aging society. While Rheumatoid arthritis (RA), an autoimmune disease, and Osteoarthritis (OA), a degenerative joint disease, have different pathogenic mechanisms, they share pathological features such as chronic synovial inflammation and irreversible cartilage damage. Current prescribed anti-inflammatory analgesics or biological agents remain symptomatic treatments that only temporarily reduce pain and slow the progression of inflammation. A fundamental disease-modifying drug capable of regenerating damaged articular cartilage or halting disease progression itself has not yet been developed.
This is because articular cartilage is surrounded by a dense, avascular extracellular matrix (ECM), which blocks the deep penetration of external substances. Even when drugs are injected directly into the joint cavity, the problem of active ingredients being lost in a short period due to synovial fluid circulation and lymphatic drainage has persisted. Therefore, there was an urgent need to develop a drug delivery vehicle that can penetrate the cartilage matrix and remain at the lesion site for a long time to lead tissue regeneration.
Key Findings
To overcome these drug delivery barriers, researchers synthesized a new ionizable lipid that increases cartilage tissue permeability. Based on this, they succeeded in designing Lipid Nanoparticles (LNPs) that stably encapsulate complex mRNA. By precisely controlling the surface charge and physical properties of the particles, they enabled deep diffusion into the dense cartilage matrix network.
Inside the LNPs, two types of messenger RNA (mRNA) providing complementary therapeutic effects were loaded together. The core components are mRNA for Interleukin-1 receptor antagonist (IL-1Ra), which blocks inflammatory pathways, and mRNA for a C-terminal truncated derivative of Angiopoietin-like 3 (ANGPTL3), which inhibits cartilage degeneration. When these two genetic factors are co-expressed in the joint, anti-inflammatory and cartilage-forming signals operate in parallel.
Therapeutic efficacy was clearly demonstrated in three different animal disease models. When intra-articular injections were performed in Collagen-Induced Arthritis (CIA) mice (a rheumatoid arthritis model) and chronic spontaneous-onset TNF-transgenic mice, synovitis and bone erosion levels were significantly alleviated. In the Destabilization of Medial Meniscus (DMM) surgical model, which induces degenerative osteoarthritis, efficacy in restoring cartilage defects to normal tissue levels was also confirmed.
Transcriptomic profiling data also supports this dual regulatory mechanism. After drug administration, inflammatory signaling and matrix-degrading enzyme expression were strongly suppressed, while anabolic gene groups for cartilage regeneration, including Type II collagen and aggrecan, significantly increased.
Significance and Outlook
This achievement is evaluated as having solved the limitations of short half-lives and low penetration power inherent in single-target protein administration through a proprietary nano-platform. Instead of administering externally produced proteins, the method induces the body's own cells to directly produce therapeutic proteins via mRNA delivery, thereby increasing therapeutic efficiency.
Several follow-up questions remain before application to actual patients. Unlike mice, human articular cartilage reaches several millimeters in thickness, so verification is required to reproduce the same penetration efficiency and protein expression levels in large animal models. It is also essential to closely examine potential immune responses and local cytotoxicity induced by the ionizable lipid during repeated intra-articular administration. Establishing a stable manufacturing process for the finished product that encapsulates two types of mRNA at a constant ratio is identified as the critical factor determining future commercialization success.
Rheumatoid arthritis (RA) and osteoarthritis (OA) are debilitating joint disorders with distinct etiologies but share common pathological features of chronic inflammation and progressive cartilage damage. Current therapeutic options are largely palliative and yet fail to achieve desired effect. In this study, we developed a combinatorial mRNA therapy using a rationally engineered lipid nanoparticle (LNP) containing a novel ionizable lipid for enhanced cartilage penetration upon intra-articular administration. This LNP co-delivers mRNAs encoding two complementary therapeutic proteins: interleukin-1 receptor antagonist (IL-1Ra) for inflammation attenuation and a C-terminal truncated derivative of angiopoietin-like 3 (ANL3) for cartilage degeneration prevention. In pre-clinical models, including collagen-induced arthritis mice, TNF-transgenic mice with spontaneous rheumatoid arthritis (RA), and the destabilization of medial meniscus (DMM) surgical osteoarthritis (OA) model, this dual therapy significantly ameliorated disease severity, reduced synovitis and bone erosion, and potently repaired cartilage damage. Mechanistically, transcriptomic profiling of joint specimens revealed that the combinatorial therapy concurrently suppressed inflammatory pathways and extracellular matrix degradation pathways, meanwhile upregulating anabolic genes facilitating chondrogenesis. Collectively, our study establishes a versatile and synergistic mRNA therapy that offers a potent disease-modifying immunomodulatory strategy capable of addressing the long-standing unmet needs in arthritis treatment.
This technology can be introduced as a disease-modifying therapeutic candidate for patients with advanced osteoarthritis, for whom there have been no clear alternatives other than surgery, to delay the timing of joint replacement surgery. If optimized as a local intra-articular injection formulation with a 6-month to 1-year cycle, it will significantly increase patient convenience and reduce systemic side effects associated with long-term medication. The possibility of expanding its use as a local joint rescue therapy for refractory rheumatoid arthritis patients who do not respond to or have developed resistance to existing antibody therapies is also open. The cartilage-penetrating LNP technology holds the potential for wide application in the development of gene therapies for other chronic joint lesions or fibrotic diseases.